

Fig. 1a




Fig. 1b




Fig. 1c




Fig. 1d

5/25




Fig. 1e

6/25




Fig. 1f

7/25




Fig. 1g




Fig. 2a

9/25




Fig. 2b

10/25




Fig. 3

11/25




Fig. 4a




Fig. 4b






Fig. 4c

14/25




Atorvastatin




Lovastatin

Fig. 5a

15/25



Pravastatin Sodium



Fluvastatin

Fig. 5b



Fig. 5c

Ragi cells

IFN- γ /Simva
L-Mevalonate

IFN- γ /Simva

IFN- γ /Atorva

IFN- γ /Lova

IFN- γ /Prava

IFN- γ

Control




Fig. 6




Fig. 7




Fig. 8





Fig. 9a

Statin treatment



CD40L staining

Fig. 9b





Fig. 9c

23/25

Day 10 after Tx



Day 14 after Tx




Fig. 10

Group	Number of Subjects
Control	7.8
Methylphenidate	4.8*
Methylphenidate + Citalopram	3.2*

Group	Number of Subjects
Control	10.2
100 mg/kg	6.8*
200 mg/kg	4.8*

Fig. 11

	³ H] Thymidine incorporation [cpm]	IFN- γ production [pg/ml]
Control	13,830 (\pm 7,078)	60,112 (\pm 13,532)
Low dose	6,508 (\pm 6,499) *	36,368 (\pm 8,005) *
High dose	5,221 (\pm 7,632) *	29,805 (\pm 8,114) *

Fig. 12